scholarly journals Influence of Antihypertensive Treatment on RAAS Peptides in Newly Diagnosed Hypertensive Patients

Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 534
Author(s):  
Annina S. Vischer ◽  
Gabriela M. Kuster ◽  
Raphael Twerenbold ◽  
Otmar Pfister ◽  
Qian Zhou ◽  
...  
Keyword(s):  
Antihypertensive Treatment ◽  
Antihypertensive Drugs ◽  
Ang Ii ◽  
First Line ◽  
Open Label ◽  
Treatment Start ◽  
Equilibrium Concentrations ◽  
Open Label Trial ◽  
Anti Inflammatory ◽  
Antihypertensive Treatments

(1) Background: Recently, influences of antihypertensive treatment on the renin–angiotensin–aldosterone system (RAAS) has gained attention, regarding a possible influence on inflammatory and anti-inflammatory pathways. We aimed to study the effects of newly initiated antihypertensive drugs on angiotensin (Ang) II and Ang (1–7) as representers of two counter-regulatory axes. (2) Methods: In this randomized, open-label trial investigating RAAS peptides after the initiation of perindopril, olmesartan, amlodipine, or hydrochlorothiazide, Ang II and Ang (1–7) equilibrium concentrations were measured at 8 a.m. and 12 a.m. at baseline and after four weeks of treatment. Eighty patients were randomized (1:1:1:1 fashion). (3) Results: Between the four substances, we found significant differences regarding the concentrations of Ang II (p < 0.0005 for 8 a.m., 12 a.m.) and Ang (1–7) (p = 0.019 for 8 a.m., <0.0005 for 12 a.m.) four weeks after treatment start. Ang II was decreased by perindopril (p = 0.002), and increased by olmesartan (p < 0.0005), amlodipine (p = 0.012), and hydrochlorothiazide (p = 0.001). Ang (1–7) was increased by perindopril and olmesartan (p = 0.008/0.002), but not measurably altered by amlodipine and hydrochlorothiazide (p = 0.317/ 0.109). (4) Conclusion: The initiation of all first line antihypertensive treatments causes early and distinct alterations of equilibrium angiotensin levels. Given the additional AT1R blocking action of olmesartan, RAAS peptides shift upon initiation of perindopril and olmesartan appear to work in favor of the anti-inflammatory axis compared to amlodipine and hydrochlorothiazide.

Hypertension in Continuous Ambulatory Peritoneal Dialysis Patients: What do we know and What can we do about It?

1999 ◽  
Vol 19 (2_suppl) ◽  
pp. 138-143 ◽  
Author(s):  
Jhoong S. Cheigh ◽  
Hyang Kim
Keyword(s):  
Risk Factors ◽  
Peritoneal Dialysis ◽  
Cardiovascular Risk ◽  
Potential Risk ◽  
Antihypertensive Treatment ◽  
Antihypertensive Drugs ◽  
Dialysis Patients ◽  
First Line ◽  
Hemodynamic Stability ◽  
Potential Risk Factors

Despite many advantages of CAPD in maintaining hemodynamic stability, approximately 50% -60% of CAPD patients have hypertension and require antihypertensive treatment. ACE inhibitors and betablockers are the preferred first-line antihypertensive drugs in these patients, but some patients may require additionallong-acting calcium antagonists to enhance antihypertensive effects. Despite antihypertensive treatment, many patients often fail to maintain BP within optimal ranges, and this fact may contribute to the high incidences of cardiovascular morbidity an d mortality. Vigilance is clearly desirable by the patient and the physician to maintain BP within target ranges most of the time. Because dialysis patients also have many other cardiovascular risk factors, the strategy to decrease cardiovascular mortality should be a combined effort targeting all potential risk factors at the same time.

scholarly journals Nebulized Azithromycin Versus Oral Azithromycin as Anti-Inflammatory Therapy in Children with Cystic Fibrosis: A Prospective Randomized Open-Label Trial

2019 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Andisheh Maneshi ◽  
Mohammad Reza Modaresi ◽  
Hossein Khalili ◽  
Lida Shojae ◽  
Toktam Faghihi
Keyword(s):  
Cystic Fibrosis ◽  
Open Label ◽  
Open Label Trial ◽  
Anti Inflammatory ◽  
Oral Azithromycin
Sign in / Sign up

Export Citation Format

Share Document